BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Cutter Capital Management LP

Cutter Capital Management LP lifted its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 41.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 560,344 shares of the company's stock after acquiring an additional 163,956 shares during the period. BridgeBio Pharma makes up about 6.3% of Cutter Capital Management LP's portfolio, making the stock its 6th largest holding. Cutter Capital Management LP owned approximately 0.30% of BridgeBio Pharma worth $15,376,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Steward Partners Investment Advisory LLC boosted its position in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after buying an additional 472 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in shares of BridgeBio Pharma in the fourth quarter worth approximately $41,000. Sterling Capital Management LLC lifted its position in shares of BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after purchasing an additional 1,514 shares in the last quarter. Avanza Fonder AB purchased a new position in BridgeBio Pharma in the fourth quarter worth $181,000. Finally, First Bank & Trust purchased a new stake in shares of BridgeBio Pharma during the 4th quarter worth approximately $205,000. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Price Performance

Shares of BBIO stock traded down $0.68 during mid-day trading on Friday, hitting $34.17. The company had a trading volume of 1,787,926 shares, compared to its average volume of 2,401,418. The stock's 50 day moving average price is $34.27 and its 200-day moving average price is $31.25. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $39.54. The company has a market capitalization of $6.49 billion, a P/E ratio of -11.99 and a beta of 1.15.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.12. The firm had revenue of $36.74 million for the quarter, compared to analysts' expectations of $57.14 million. The company's revenue for the quarter was down 44.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.20) EPS. On average, equities research analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Redburn Atlantic began coverage on BridgeBio Pharma in a research report on Monday, March 31st. They set a "buy" rating and a $50.00 target price on the stock. HC Wainwright upped their price target on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. Cantor Fitzgerald reiterated an "overweight" rating and set a $95.00 price target on shares of BridgeBio Pharma in a research report on Friday, February 21st. UBS Group upped their price target on BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Finally, Scotiabank increased their price objective on BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $57.09.

Insider Activity

In other news, CAO Maricel Apuli sold 1,026 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $38.51, for a total value of $39,511.26. Following the completion of the sale, the chief accounting officer now directly owns 147,639 shares of the company's stock, valued at $5,685,577.89. This trade represents a 0.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Andrew Lo sold 100,000 shares of the stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $38.50, for a total transaction of $3,850,000.00. Following the completion of the sale, the director now directly owns 105,583 shares in the company, valued at $4,064,945.50. This trade represents a 48.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,410,217 shares of company stock worth $212,434,332. 24.66% of the stock is currently owned by insiders.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.